Public Policy Resources

The Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is highly effective at detecting and treating breast and cervical cancer in low-income, uninsured, and underinsured women – who may otherwise not be screened. The American Cancer Society Cancer Action Network (ACS CAN) urges Congress to reauthorize this critical program by passing the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act.

For 30 years, the Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program has decreased disparities in breast and cervical cancer deaths.

In 2024, an estimated 13,820 people in the U.S. will be diagnosed with invasive cervical cancer, and 4,360 will die from the disease. Cervical cancer can affect any person with a cervix and most often is caused by certain types of human papillomavirus (HPV). Persistent HPV infection causes almost all cervical cancers but fortunately there is a safe and effective vaccine against HPV.

The PSA Screening for HIM Act  (H.R. 1826/S. 2821) would remove out-of-pocket costs for prostate cancer screening for those at highest risk for the disease. 

Approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer in her lifetime, and 1 in 39 women (3%) will die from breast cancer. In 2023, an estimated 297,790 women in the U.S. will be diagnosed with invasive breast cancer, and 43,170 will die from the disease. Despite the fact that U.S. breast cancer death rates have been declining for several decades, not all people have benefited equally from the advances in prevention, early detection, and treatments that have helped achieve these lower rates.

Critical steps are needed to increase lung cancer screening rates across the country and also increasing to access comprehensive cessation benefits, especially among individuals with limited incomes that are disproportionately burdened by lung cancer.

ACS CAN supports H.R. 4286 to eliminate barriers and increase access to lung cancer screening and expand coverage for tobacco cessation.

Breast cancer is the second most diagnosed cancer among women in the U.S. and the second leading cause of cancer death among women after lung cancer. Ensuring breast cancer screening services ― including diagnostic and follow-up testing ― are covered without no cost-sharing is essential to increasing access and expanding coverage of breast cancer screening.

ACS CAN supports H.R. 3086 to increase access to no cost breast cancer screening, diagnostic and follow-up testing.

ACS CAN supports the Women and Lung Cancer Research and Preventive Services Act of 2023 by to accelerate progress in reducing mortality from lung cancer, including among women.

Our ability to continue to make progress against cancer relies heavily on eliminating inequities that exist in breast cancer prevention and treatment. That is why ACS CAN advocates for policies to reduce the disparities in breast cancer by improving access to prevention and early detection services, patient navigation services, insurance coverage, in-network facilities, and clinical trials.